Skip to main content

Find a clinical trial

Find a clinical trial

Trial status
Trial Phase
Trial type
33 clinical trials grid list download
  • Titre Organe Phase Statut Crittères majeurs d'inclusion Contact
  • 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Tumeur maligne phase 1 Ouvert any line, RECIST 1.1 Ahmad Hussein Awada
  • ADRIATIC A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) Poumon phase 3 Ouvert 4 lines chemotherapy and radiation Bogdan Grigoriu
  • AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiples phase 1/1b Fermé any line, RECIST 1.1 Philippe Aftimos
  • AMG510 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Multiples phase 1/2 Ouvert Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation Nuria Kotecki
  • ANAM-17-21 A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC) NSCLC phase 3 Ouvert Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior Thierry Berghmans
  • Apple APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients Poumon phase 3 Fermé EGFR activating mutation associated with EGFR-TKI sensitivity Thierry Berghmans
  • B079201215796 Role of bronchoscopy assisted by electromagnetic navigation (EMN) in the diagnosis of small pulmonary nodules of indeterminate nature. A prospective study by the European Lung Cancer Working Party Poumon phase 2 Ouvert Nodule 5-20 mm of undetermined nature in at least one lung. Thierry Berghmans
  • B079201523324 Does inflammation have a significant implication in Lung Cancer evolution? Poumon Ouvert Lung cancerNo prior treatment Anne-Pascale Meert
  • CANFOUR An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Multiples phase 1/2 Ouvert Metastatic Christiane Jungels
  • CLDK378A2303 A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib Multiples phase 3 Fermé Anaplasic lymphoma kinase (ALK) positive Thierry Berghmans
  • D5164C00001 ADAURA A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) NSCLC phase 3 Fermé EGFR mutation : Ex19del, L858R, alone or in combination with T790M mutation. Thierry Berghmans
  • EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Poumon Fermé any line / Lung metastasis Konstantinos Stathopoulos
  • ETOP 12-17 ALERT-lung A single arm phase II trial evaluating the activity of alectinib for the treatment of pretreated RET-rearranged advanced NSCLC (ETOP 12-17 ALERT-lung) NSCLC phase 2 Ouvert At least one prior platinum-based systemic regimen/ RET Thierry Berghmans
  • I3Y-MC-JPBO A phase II study of Abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer, non-small cell lung cancer, or melanoma Multiples phase 2 Fermé Brain metastasis Ahmad Hussein Awada